Loading
Obesity / Glp-1 Receptor Agonists · Journal article
Journal of Diabetes and Metabolic Disorders · July 7, 2026
Well-designed and adequately powered for the question it asks.
This meta-analysis of five RCTs in Chinese adults demonstrates that GLP-1 receptor agonists produce statistically significant and clinically meaningful reductions in body weight, waist circumference, HbA1c, fasting glucose, cholesterol, and blood pressure compared with placebo. Gastrointestinal adverse events were increased but serious adverse events were not, supporting the use of GLP-1RAs as effective metabolic risk reduction therapy in this population.
Systematic review and meta-analysis of randomized controlled trials. Overweight or obese Chinese adults participating in randomized controlled trials comparing GLP-1RAs or dual GLP-1/GIP receptor agonists with placebo. Intervention: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) or dual GLP-1/GIP receptor agonists. Compared with: Placebo. n = 2,204.
Body weight reduction of -10.06 kg (95% CI: -15.56 to -4.56) with GLP-1RAs Waist circumference reduction of -7.06 cm (95% CI: -9.85 to -4.26) HbA1c reduction of -0.41% (95% CI: -0.56 to -0.27)
Individual serious adverse event counts and types not specified Long-term efficacy and safety beyond trial durations not addressed
Clinicians can consider GLP-1RAs as evidence-based therapy for cardio-metabolic risk reduction in overweight and obese Chinese patients, with expectation of clinically meaningful weight loss and improvements in glycemic control and blood pressure. Gastrointestinal side effects should be discussed with patients, though serious adverse events were not increased.
Meta-analysis of 5 RCTs in 2,204 Chinese adults demonstrates consistent, clinically meaningful reductions across multiple cardio-metabolic outcomes with acceptable safety, providing robust evidence for GLP-1RA efficacy in this population.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians can consider GLP-1RAs as evidence-based therapy for cardio-metabolic risk reduction in overweight and obese Chinese patients, with expectation of clinically meaningful weight loss and improvements in glycemic control and blood pressure. Gastrointestinal side effects should be discussed with patients, though serious adverse events were not increased.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated substantial weight loss and metabolic benefits in overweight and obese populations. However, their cardio-metabolic efficacy and safety profile in Chinese adults remain incompletely characterized.Methods. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing GLP-1RAs or dual GLP-1/GIP receptor agonists with placebo in overweight or obese Chinese adults. Searches were performed in PubMed, Cochrane CENTRAL, and Scopus from inception to October 12, 2025. Outcomes included changes in body weight, waist circumference, HbA1c, fasting glucose, cholesterol, systolic and diastolic blood pressure, and adverse events. Effect sizes were pooled using random-effects models and reported as mean differences (MDs) or risk ratios (RRs) with 95% confidence intervals (CIs).Results. Five RCTs comprising 2,204 participants were included, of whom 1,522 received GLP-1RA therapy and 682 received placebo. GLP-1RAs significantly reduced body weight (MD: -10.06 kg; 95% CI: -15.56 to - 4.56), waist circumference (MD: -7.06 cm; 95% CI: -9.85 to - 4.26), HbA1c (MD: -0.41%; 95% CI: -0.56 to - 0.27), fasting glucose (MD: -0.48 mmol/L; 95% CI: -0.69 to - 0.27), cholesterol (MD: -7.95 mg/dL; 95% CI: -9.57 to - 6.33), systolic blood pressure (MD: -4.26 mmHg; 95% CI: -6.28 to - 2.23), and diastolic blood pressure (MD: -2.44 mmHg; 95% CI: -3.70 to - 1.18). GLP-1RAs were associated with increased risks of gastrointestinal adverse events, including nausea, diarrhea, and vomiting, but not serious adverse events.Conclusion. Among overweight or obese Chinese adults, GLP-1RAs produce clinically significant improvements in body weight and multiple cardiometabolic risk factors while maintaining an acceptable safety profile. These findings support the role of GLP-1RAs as effective long-term therapeutic options for metabolic risk reduction in this population.Clinical trial registration. Not applicable.Supplementary information. The online version contains supplementary material available at 10.1007/s40200-026-02000-8.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.